Medication info

Pernobon Injection 1% (Polininate Calcium)

Prescription medicationInjectionsIntravenous injection
Ingredient · strength
Calcium Folinate›10.8mg / 1mL
Manufacturer / importer
Samjin Pharmaceutical Co., Ltd.
Appearance
A colorless to pale yellow transparent solution in a brown glass vial
Packaging
10 vials/box [5mL/vial], 10 vials/box [10mL/vial], 5 vials/box [20mL/vial], 1 vial/box [30mL/vial], 1 vial/box [50mL/vial]
Approval status
Active

MFDS item code 201101492 · Notified 2011.03.17 · Insurance code 647803511,647803521,647803531,647803541,

Summary

Main use
5-FU combination therapy for advanced colorectal cancer; alleviation of toxicity from folate antagonists
Who receives it
Adults
Adult administration
1. Standard methotrexate therapy: If adverse reactions occur with the usual dose of methotrexate (a folate antagonist), administer 6-12mg of folinate per dose by intramuscular injection every 6 hours, 4 times daily. In the event of methotrexate overdose, administer an amount equal to the dose of methotrexate given. 2. Methotrexate-folinate rescue therapy: Starting 3 hours after completion of methotrexate administration, administer 15mg of folinate per dose by intravenous injection every 3 hours for 9 doses, followed by intravenous or intramuscular injection every 6 hours for 8 doses. If severe adverse reactions considered to be caused by methotrexate occur, increase the dose and extend the duration of administration. 3. Combination therapy with 5-Fluorouracil (5-FU) for advanced colorectal cancer: Select one of the two regimens. 1) Slowly administer calcium folinate 200mg/㎡ intravenously over at least 3 minutes, followed by intravenous administration of 5-FU 370mg/㎡. 2) Administer calcium folinate 20mg/㎡ intravenously, followed by intravenous administration of 5-FU 425mg/㎡. Do not administer them simultaneously, as precipitation of 5-FU and folinate may occur. Continue the above treatment for 5 days and repeat at 4-week intervals.

Ingredients

Manufacturer
Samjin Pharmaceutical Co., Ltd.

Efficacy & effects

5-FU combination therapy for advanced colorectal cancer; alleviation of toxicity from folate antagonists

View approved original text

This medication reduces the toxicity of folate metabolism antagonists by regulating the folate metabolic pathway. It is also used to enhance the treatment effect in patients with advanced colon cancer when administered together with 5-Fluorouracil (5-FU).

How it is given

Adult administration

1. Standard methotrexate therapy: If adverse reactions occur with the usual dose of methotrexate (a folate antagonist), administer 6-12mg of folinate per dose by intramuscular injection every 6 hours, 4 times daily. In the event of methotrexate overdose, administer an amount equal to the dose of methotrexate given. 2. Methotrexate-folinate rescue therapy: Starting 3 hours after completion of methotrexate administration, administer 15mg of folinate per dose by intravenous injection every 3 hours for 9 doses, followed by intravenous or intramuscular injection every 6 hours for 8 doses. If severe adverse reactions considered to be caused by methotrexate occur, increase the dose and extend the duration of administration. 3. Combination therapy with 5-Fluorouracil (5-FU) for advanced colorectal cancer: Select one of the two regimens. 1) Slowly administer calcium folinate 200mg/㎡ intravenously over at least 3 minutes, followed by intravenous administration of 5-FU 370mg/㎡. 2) Administer calcium folinate 20mg/㎡ intravenously, followed by intravenous administration of 5-FU 425mg/㎡. Do not administer them simultaneously, as precipitation of 5-FU and folinate may occur. Continue the above treatment for 5 days and repeat at 4-week intervals.

Precautions

This drug is not suitable for the treatment of pernicious anemia due to vitamin B12 deficiency or other macrocytic anemias. Even if neurological symptoms continue to progress, blood status may improve temporarily, so caution is advised. Women who are pregnant or breastfeeding should not receive this drug, especially in combination with 5-FU. However, it should be used with caution in pregnant or lactating women when administered to mitigate the toxicity of folate antagonists. This drug can cause hypersensitivity reactions such as anaphylaxis or allergic reactions like urticaria, and pain or discomfort at the injection site may occur. Additionally, fever or central nervous system symptoms, such as paralysis, excitement, and depression, may also occur. When used with 5-FU, diarrhea, skin problems, mucositis, conjunctivitis, and blood abnormalities may occur, requiring dosage adjustments of 5-FU if symptoms are severe. This medication should be used in conjunction with methotrexate under the guidance of a physician experienced in chemotherapy, and it should be administered promptly in case of folate antagonist overdose for better efficacy. Proper dosages and treatment duration should be determined while monitoring the methotrexate concentration in the blood. In particular, in cases with impaired kidney function or fluid retention in the body, the excretion of methotrexate may be delayed, allowing for high doses of this drug to be administered intravenously. This drug uses transporters like methotrexate, so patients who are resistant to methotrexate may be resistant to this drug as well. If there is a possibility of vomiting, it is recommended to administer this drug via injection rather than orally. In patients with central nervous system tumors, repeated administration of this drug may accumulate in the body and reduce the anticancer effect of methotrexate, so overdose should be avoided. This drug is not used for the treatment of macrocytic anemia caused by DNA synthesis inhibitors, and it is ineffective for other adverse reactions aside from blood toxicity due to methotrexate. When used in combination with 5-FU, regular blood tests and liver function tests should be conducted before and during treatment, and if adverse reactions occur, the dosage of 5-FU should be adjusted. This drug may increase liver metabolism, lowering the blood concentration of some anticonvulsants and increasing the risk of seizures, thus requiring blood concentration monitoring during administration. For pregnant women, the risk to the fetus should be carefully considered before administering this drug, and caution should be exercised in nursing women as well. In elderly patients, especially when used with 5-FU, the risk of gastrointestinal toxicity is increased, so care should be taken, and generally, elderly individuals should be cautious with medication use due to decreased physical function. This drug is contraindicated for intrathecal administration and has a calcium component; therefore, intravenous administration should be limited to a rate of 160mg per minute.

Side effects

  • Anaphylactic reactions
  • urticaria
  • vascular pain
  • transient pain
  • fever
  • paralysis
  • agitation
  • depression
  • diarrhea
  • skin reactions
Show 6 more
  • skin dryness
  • stomatitis
  • conjunctivitis
  • mucositis
  • mild myelotoxicity
  • leukopenia

Not everyone experiences these, and they can vary from person to person.

Storage

This drug is sensitive to light and should be stored away from direct sunlight. Additionally, it should be stored in a sealed container to prevent exposure to air, and the appropriate storage temperature is refrigeration between 2 degrees and 8 degrees Celsius. Therefore, it is safe to store it inside the refrigerator.

Appearance and packaging

Appearance

A colorless to pale yellow transparent solution in a brown glass vial

Package unit

10 vials/box [5mL/vial], 10 vials/box [10mL/vial], 5 vials/box [20mL/vial], 1 vial/box [30mL/vial], 1 vial/box [50mL/vial]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.